Mesa Laboratories (Nasdaq:MLAB) - Stock Price, News & Analysis

MLAB Stock Overview

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally.

MLAB fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Earnings are forecast to grow 86.86% per year

Risk Analysis

Interest payments are not well covered by earnings

Shareholders have been diluted in the past year

My Notes

New

Notes are coming soon

Mesa Laboratories, Inc. Competitors

Heska

NasdaqCM:HSKA

US$946.0m

LeMaitre Vascular

NasdaqGM:LMAT

US$1.0b

Paragon 28

NYSE:FNA

US$1.4b

Cutera

NasdaqGS:CUTR

US$671.0m

Price History & Performance

Summary of all time highs, changes and price drops for Mesa Laboratories
Historical stock prices
Current Share Price	US$193.27
52 Week High	US$286.20
52 Week Low	US$114.21
Beta	0.65
1 Month Change	16.28%
3 Month Change	46.18%
1 Year Change	-30.90%
3 Year Change	-26.36%
5 Year Change	26.44%
Change since IPO	6,210.86%

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%

Apr 09

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Dec 08

Here's Why Mesa Laboratories (NASDAQ:MLAB) Can Manage Its Debt Responsibly

Aug 13

Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Intrinsic Value Is Potentially 26% Below Its Share Price

May 28

Here's What's Concerning About Mesa Laboratories' (NASDAQ:MLAB) Returns On Capital

May 04

Have Mesa Laboratories, Inc. (NASDAQ:MLAB) Insiders Been Selling Their Stock?

Feb 26

How Much Does Mesa Laboratories' (NASDAQ:MLAB) CEO Make?

Feb 08

Has Mesa Laboratories (NASDAQ:MLAB) Got What It Takes To Become A Multi-Bagger?

Jan 18

These 4 Measures Indicate That Mesa Laboratories (NASDAQ:MLAB) Is Using Debt Reasonably Well

Dec 28

Shareholders Are Thrilled That The Mesa Laboratories (NASDAQ:MLAB) Share Price Increased 156%

Dec 07

Shareholder Returns

	MLAB	US Medical Equipment	US Market
7D	-1.8%	-0.2%	2.8%
1Y	-30.9%	-9.7%	-9.2%

Return vs Industry: MLAB underperformed the US Medical Equipment industry which returned -9.7% over the past year.

Return vs Market: MLAB underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is MLAB's price volatile compared to industry and market?
MLAB volatility
MLAB Average Weekly Movement	7.9%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.9%
10% most volatile stocks in US Market	17.3%
10% least volatile stocks in US Market	2.8%

Stable Share Price: MLAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MLAB's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1982	681	Gary Owens	https://www.mesalabs.com

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company’s Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry.

Mesa Laboratories, Inc. Fundamentals Summary

How do Mesa Laboratories's earnings and revenue compare to its market cap?
MLAB fundamental statistics
Market Cap	US$1.03b
Earnings (TTM)	-US$3.98m
Revenue (TTM)	US$222.78m

4.6x

P/S Ratio

-259.4x

P/E Ratio

Is MLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MLAB income statement (TTM)
Revenue	US$222.78m
Cost of Revenue	US$83.85m
Gross Profit	US$138.93m
Other Expenses	US$142.90m
Earnings	-US$3.98m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 06, 2023

Earnings per share (EPS)	-0.75
Gross Margin	62.36%
Net Profit Margin	-1.78%
Debt/Equity Ratio	52.6%

How did MLAB perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

-85%

Payout Ratio

Does MLAB pay a reliable dividends?

See MLAB dividend history and benchmarks

When do you need to buy MLAB by to receive an upcoming dividend?
Mesa Laboratories dividend dates
Ex Dividend Date	Feb 27 2023
Dividend Pay Date	Mar 15 2023
Days until Ex dividend	29 days
Days until Dividend pay date	45 days

Does MLAB pay a reliable dividends?

See MLAB dividend history and benchmarks

MLAB Stock Overview

Rewards

Risk Analysis

Mesa Laboratories, Inc. Competitors

NasdaqCM:HSKA

US$946.0m

NasdaqGM:LMAT

US$1.0b

NYSE:FNA

US$1.4b

NasdaqGS:CUTR

US$671.0m

Price History & Performance

Recent News & Updates

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Upcoming dividend of US$0.16 per share

Recent updates

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Upcoming dividend of US$0.16 per share

Now 21% undervalued after recent price drop

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

VP, CFO & Chief Accounting Officer exercised options and sold US$143k worth of stock

Upcoming dividend of US$0.16 per share

Independent Director recently sold US$198k worth of stock

VP, CFO & Chief Accounting Officer exercised options and sold US$260k worth of stock

Independent Director recently bought US$100k worth of stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop

Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022

Chairman of the Board exercised options to buy US$3.8m worth of stock.

Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2022

Mesa Laboratories, Inc. Appoints Tony Tripeny to Its Board of Directors

CEO, President & Director recently sold US$331k worth of stock

Consensus forecasts updated

Price target decreased to US$253

Chairman of the Board exercised options and sold US$712k worth of stock

Consensus forecasts updated

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of US$0.16 per share

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Price target decreased to US$298

Mesa Laboratories, Inc. Announces Termination of Greg DiNoia as Senior Vice President of Commercial Operations, Effective June 30, 2022

Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%

Price target decreased to US$298

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2022

Price target decreased to US$307

Chairman of the Board exercised options and sold US$860k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director exercised options and sold US$230k worth of stock

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Independent Director exercised options and sold US$508k worth of stock

Upcoming dividend of US$0.16 per share

CFO & Chief Accounting Officer exercised options and sold US$219k worth of stock

Insider recently sold US$91k worth of stock

Second quarter 2022 earnings released: EPS US$0.71 (vs US$0.52 in 2Q 2021)

CFO & Chief Accounting Officer exercised options and sold US$424k worth of stock

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million.

CFO & Chief Accounting Officer exercised options and sold US$253k worth of stock

Independent Director recently sold US$161k worth of stock

Upcoming dividend of US$0.16 per share

CFO & Chief Accounting Officer exercised options and sold US$185k worth of stock

Insider recently sold US$179k worth of stock

Here's Why Mesa Laboratories (NASDAQ:MLAB) Can Manage Its Debt Responsibly

Consensus forecasts updated

Chairman of the Board notifies of intention to sell stock

Key Executive exercised options and sold US$189k worth of stock

Key Executive exercised options and sold US$177k worth of stock